ITGA2 and ovarian carcinoma: Combining ITGA2 knockdown with PTX treatment caused a more remarkable decrease in tumor volume and tumor mass, suggesting that knocking down ITGA2 could inhibit PTX resistance and also enhance the therapeutic ability of PTX in ovarian cancer in vivo.